...
首页> 外文期刊>Cell Communication and Signaling >N822K- or V560G-mutated KIT activation preferentially occurs in lipid rafts of the Golgi apparatus in leukemia cells
【24h】

N822K- or V560G-mutated KIT activation preferentially occurs in lipid rafts of the Golgi apparatus in leukemia cells

机译:N822K或V560G突变的KIT激活优先发生在白血病细胞中高尔基体的脂质筏中

获取原文
           

摘要

KIT tyrosine kinase is expressed in mast cells, interstitial cells of Cajal, and hematopoietic cells. Permanently active KIT mutations lead these host cells to tumorigenesis, and to such diseases as mast cell leukemia (MCL), gastrointestinal stromal tumor (GIST), and acute myeloid leukemia (AML). Recently, we reported that in MCL, KIT with mutations (D816V, human; D814Y, mouse) traffics to endolysosomes (EL), where it can then initiate oncogenic signaling. On the other hand, KIT mutants including KITD814Y in GIST accumulate on the Golgi, and from there, activate downstream. KIT mutations, such as N822K, have been found in 30% of core binding factor-AML (CBF-AML) patients. However, how the mutants are tyrosine-phosphorylated and where they activate downstream molecules remain unknown. Moreover, it is unclear whether a KIT mutant other than KITD816V in MCL is able to signal on EL. We used leukemia cell lines, such as Kasumi-1 (KITN822K, AML), SKNO-1 (KITN822K, AML), and HMC-1.1 (KITV560G, MCL), to explore how KIT transduces signals in these cells and to examine the signal platform for the mutants using immunofluorescence microscopy and inhibition of intracellular trafficking. In AML cell lines, KITN822K aberrantly localizes to EL. After biosynthesis, KIT traffics to the cell surface via the Golgi and immediately migrates to EL through endocytosis in a manner dependent on its kinase activity. However, results of phosphorylation imaging show that KIT is preferentially activated on the Golgi. Indeed, blockade of KITN822K migration to the Golgi with BFA/M-COPA inhibits the activation of KIT downstream molecules, such as AKT, ERK, and STAT5, indicating that KIT signaling occurs on the Golgi. Moreover, lipid rafts in the Golgi play a role in KIT signaling. Interestingly, KITV560G in HMC-1.1 migrates and activates downstream in a similar manner to KITN822K in Kasumi-1. In AML, KITN822K mislocalizes to EL. Our findings, however, suggest that the mutant transduces phosphorylation signals on lipid rafts of the Golgi in leukemia cells. Unexpectedly, the KITV560G signal platform in MCL is similar to that of KITN822K in AML. These observations provide new insights into the pathogenic role of KIT mutants as well as that of other mutant molecules.
机译:KIT酪氨酸激酶在肥大细胞,Cajal间质细胞和造血细胞中表达。永久活跃的KIT突变导致这些宿主细胞发生肿瘤,并导致诸如肥大细胞白血病(MCL),胃肠道间质瘤(GIST)和急性髓细胞白血病(AML)等疾病。最近,我们报道了在MCL中,具有突变的KIT(D816V,人; D814Y,小鼠)运输到了溶酶体(EL),然后它可以启动致癌信号。另一方面,包括GIST中的KITD814Y在内的KIT突变体在高尔基体上积累,并从那里激活下游。在30%的核心结合因子AML(CBF-AML)患者中发现了KIT突变,例如N822K。然而,突变体如何被酪氨酸磷酸化以及它们在何处激活下游分子仍是未知的。而且,不清楚MCL中除KITD816V以外的KIT突变体是否能够在EL上发信号。我们使用了白血病细胞系,例如Kasumi-1(KITN822K,AML),SKNO-1(KITN822K,AML)和HMC-1.1(KITV560G,MCL),来探索KIT如何在这些细胞中转导信号并检查信号使用免疫荧光显微镜和抑制细胞内运输的突变体的平台。在AML细胞系中,KITN822K异常定位于EL。生物合成后,KIT通过高尔基体运输到细胞表面,并通过内吞作用立即迁移到EL,这取决于其激酶活性。但是,磷酸化成像的结果表明,KIT在高尔基体上被优先激活。实际上,用BFA / M-COPA阻止KITN822K迁移到高尔基体会抑制KIT下游分子(如AKT,ERK和STAT5)的激活,表明KIT信号发生在高尔基体上。此外,高尔基体中的脂筏在KIT信号传导中起作用。有趣的是,HMC-1.1中的KITV560G以与Kasumi-1中的KITN822K类似的方式向下游迁移和激活。在AML中,KITN822K错误地定位到EL。然而,我们的发现表明,该突变体在白血病细胞中的高尔基体脂筏上转导了磷酸化信号。出乎意料的是,MCL中的KITV560G信号平台类似于AML中的KITN822K。这些观察结果提供了对KIT突变体以及其他突变分子的致病作用的新见解。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号